- Updated timelines for LCA10 Investigational New Drug (IND) application submission. The target date for filing the IND application for the LCA10 program is being moved to the middle of 2018 to accommodate certain delays in third-party manufacturing of our LCA10 product candidate and to take full advantage of our newly formed alliance with
Allergan .
Tuesday, May 16, 2017
Editas Delays IND for lead Crispr Program Until Mid 2018
Original date forecast was end of 2017
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment